# To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis

> **NCT02463643** · PHASE2 · COMPLETED · sponsor: **Zeria Pharmaceutical** · enrollment: 503 (actual)

## Conditions studied

- Esophagitis, Reflux

## Interventions

- **DRUG:** Z-215 10mg
- **DRUG:** Z-215 20mg
- **DRUG:** Z-215 Placebo
- **DRUG:** Rabeprazole Sodium
- **DRUG:** Rabeprazole Sodium Placebo

## Key facts

- **NCT ID:** NCT02463643
- **Lead sponsor:** Zeria Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-10
- **Final completion:** 2017-03
- **Target enrollment:** 503 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02463643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02463643, "To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02463643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*